GE Announces New Life Sciences Business

By combining two existing businesses, Protein Separations and Discovery Systems, GE Healthcare (Chalfont St. Giles, UK) has created a new Life Sciences business.

The new business is focused on five segments: bio process, protein sciences, discovery sciences, genomic sciences, and services. This new global organization is led by Peter Ehrenheim, president and CEO of GE Healthcare Life Sciences, who previously headed the company's Protein Separations business and is based in Uppsala (Sweden).

"The business has a bright future ahead, and I firmly believe this is the right structure to achieve our goals,” said Mr. Ehrenheim. "We are taking these steps today to become a larger player in the Life Sciences market. Our new Life Science organization has unique skills that we can leverage by providing an increased focus on the five business segments. I am particularly excited by the opportunities this business has in the protein sciences area.”

Proteins have become an area of increasing interest. After the genomic breakthroughs in the 1990s, the focus has centered on protein sciences, which play an important role in understanding, predicting, and curing different diseases. Biopharmaceutical drugs based on proteins are a rapidly growing segment of the pharmaceutical market. Currently, there are 150 biopharmaceuticals on the market and many more are in the pipeline.




Related Links:
GE Healhcare